{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:06:31Z","timestamp":1772168791539,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.128116.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000}}],"reference-count":54,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>\n                    <ns4:bold>Background:<\/ns4:bold>\n                    This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF).\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Methods:<\/ns4:bold>\n                    A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for 24 weeks at H. Adam Malik and USU Hospitals in Medan, Indonesia. The history of the samples was obtained, followed by physical examination, and blood collection. CTLA-4 polymorphism examination was carried out using real-time PCR, while the serum CTLA-4 levels were assessed with ELISA.\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Results:\u00a0<\/ns4:bold>\n                    The CTLA-4 -1661G&gt;A polymorphism, genotype GG+AG, increased 1.52 times risk of not achieving HBV DNA suppression to TDF compared to genotype AA (p=0.041). High CTLA-4 levels increased 2.28 times risk, high HBV DNA levels increased 2.09 times risk, low ALT levels increased 1.95 times risk of not achieving HBV DNA suppression (p= 0.009, 0.026, 0.036, respectively). There was no relationship between gender, age, ethnicity, obesity, baseline AST, HBeAg, genotype, liver fibrosis and HBV DNA suppression after 24 weeks of treatment (p&gt;0.05).\n                  <\/ns4:p>\n                  <ns4:p>\n                    <ns4:bold>Conclusions:<\/ns4:bold>\n                    The levels of CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G&gt;A polymorphism have a potential relationship with the suppression of HBV DNA in chronic hepatitis B patients with TDF.\n                  <\/ns4:p>","DOI":"10.12688\/f1000research.128116.2","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:45:07Z","timestamp":1692873907000},"page":"1521","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate"],"prefix":"10.12688","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-168X","authenticated-orcid":false,"given":"Darmadi","family":"Darmadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharma","family":"Lindarto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelita","family":"Siregar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6230-6943","authenticated-orcid":false,"given":"Tri","family":"Widyawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Rusda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Mahmud","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5822-300X","authenticated-orcid":false,"given":"Fauzi","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putri Chairani","family":"Eyanoer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masrul","family":"Lubis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imelda","family":"Rey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/1743-422X-7-160","article-title":"Hepatitis B Virus genotypes and precore and core mutants in UAE Patients.","volume":"7","author":"M Alfaresi","year":"2010","journal-title":"Virol J."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"122-130","DOI":"10.20517\/2394-5079.2015.53","article-title":"Can gender predict virological response to standard antiviral therapy for chronic Hepatitis C? A retrospective study.","volume":"2","author":"P Belci","year":"2016","journal-title":"Hepatoma Res."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"699-705","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.","volume":"56","author":"F Bonino","year":"2007","journal-title":"Gut."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11894-014-0372-6","article-title":"Utilization of fibroscan in clinical practice.","volume":"16","author":"A Bonder","year":"2014","journal-title":"Curr Gastroenterol Rep."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"645-652","DOI":"10.3892\/mmr.2013.1825","article-title":"Influence of cytotoxic T Lymphocyte-associated antigen 4 polymorphisms on the outcomes of hepatitis B virus infection.","volume":"9","author":"M Chen","year":"2014","journal-title":"Mol Med Rep."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4492-4500","DOI":"10.1007\/s10620-020-06761-x","article-title":"Advanced liver fibrosis is associated with necroinflammatory grade but not hepatic steatosis in chronic Hepatitis B Patients.","volume":"66","author":"Y Chen","year":"2021","journal-title":"Dig Dis Sci."},{"key":"ref13","first-page":"237-246","article-title":"Foxp3, PD-1 and CTLA-4 are decreased significantly after a tenofovir therapy in patients with chronic hepatitis B.","volume":"15","author":"H Cho","year":"2020","journal-title":"Futur Virol."},{"key":"ref16","doi-asserted-by":"publisher","author":"D Darmadi","year":"2022a","DOI":"10.6084\/m9.figshare.21471264.v1"},{"key":"ref17","doi-asserted-by":"publisher","author":"D Darmadi","year":"2022b","DOI":"10.6084\/m9.figshare.21651587.v1"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.21564474.v1","article-title":"Informed Consent. figshare.","author":"D Darmadi","year":"2022c","journal-title":"Journal contribution."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1279-1305","DOI":"10.3390\/v2061279","article-title":"Antiviral treatment of chronic hepatitis B virus (HBV) infections.","volume":"2","author":"E De Clercq","year":"2010","journal-title":"Viruses."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"175-182","DOI":"10.4292\/wjgpt.v5.i3.175","article-title":"Prevention of hepatocellular carcinoma in patients with chronic hepatitis B.","volume":"5","author":"C Fern\u00e1ndez-Rodr\u00edguez","year":"2014","journal-title":"World J Gastrointest Pharmacol. Ther."},{"key":"ref22","first-page":"235-242","article-title":"Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus.","volume":"51","author":"C Fierbin\u0163eanu-Braticevici","year":"2010","journal-title":"Romanian J Morphol Embryol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3603-3610","DOI":"10.1016\/j.vaccine.2013.05.003","article-title":"Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine.","volume":"31","author":"D Frasca","year":"2013","journal-title":"Vaccine."},{"key":"ref27","first-page":"160-162","article-title":"Liver biopsy interpretation & the regression of hepatitis B virus related cirrhosis.","volume":"140","author":"F Grizzi","year":"2014","journal-title":"Indian J Med Res."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1222-1232","DOI":"10.1038\/s41423-019-0289-y","article-title":"The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing ctla-4 transcription.","volume":"17","author":"J Guo","year":"2020","journal-title":"Cell Mol Immunol."},{"key":"ref28","first-page":"30-36","article-title":"What is the real function of the liver \u2018function\u2019 tests?","volume":"81","author":"P Hall","year":"2012","journal-title":"Ulster Med J."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"335-339","DOI":"10.3760\/cma.j.issn.1007-3418.2013.05.006","article-title":"Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B.","volume":"21","author":"Y Ji","year":"2013","journal-title":"Zhonghua Gan Zang Bing Za Zhi."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"634-651","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C.","volume":"49","author":"A Kau","year":"2008","journal-title":"J Hepatol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"637-645","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.","volume":"143","author":"P Kennedy","year":"2012","journal-title":"Gastroenterology."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1050-1059","DOI":"10.1002\/bies.201200099","article-title":"Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.","volume":"34","author":"S Klein","year":"2012","journal-title":"Bioessays."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"69-83","DOI":"10.1002\/hep.29155","article-title":"Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.","volume":"66","author":"A Kosinska","year":"2017","journal-title":"Hepatology."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"161-168","DOI":"10.1016\/j.jkss.2012.07.001","article-title":"A simple test for homogeneity of Hardy-Weinberg equilibrium and disequilibrium across strata.","volume":"42","author":"J Kim","year":"2013","journal-title":"J Korean Stat Soc."},{"key":"ref78","doi-asserted-by":"publisher","first-page":"431-439","DOI":"10.1002\/eji.201343649","article-title":"FoxP3 provide competitive fitness to CD4+CD25+ T cells in leprosy patients via transcriptional regulation.","volume":"44","author":"S Kumar","year":"2014","journal-title":"Eur H Immunol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"302-311","DOI":"10.1016\/j.jfma.2013.02.001","article-title":"Hepatitis B viral factors and treatment responses in chronic Hepatitis B.","volume":"112","author":"C Lin","year":"2013","journal-title":"J Formos Med Assoc."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1419-1428","DOI":"10.1111\/j.1365-2036.2007.03506.x","article-title":"Clinical trial: effects of adefovir dipivoxil therapy in asian and caucasian patients with chronic hepatitis B.","volume":"26","author":"S Lim","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1014-1017","DOI":"10.1080\/21645515.2016.1274475","article-title":"Influences of obesity on the immunogenicity of hepatitis B vaccine.","volume":"13","author":"F Liu","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"8-20","DOI":"10.1002\/hep4.1436","article-title":"Hepatitis B treatment: what we know now and what remains to be researched.","volume":"4","author":"A Lok","year":"2019","journal-title":"Hepatol Commun."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"468-475","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.","volume":"381","author":"P Marcellin","year":"2013","journal-title":"Lancet."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"265-275","DOI":"10.1097\/QAI.0b013e3182185276","article-title":"Tenofovir selectively regulates production of inflammatory cytokines and shifts the Il-12\/Il-10 balance in human primary cells.","volume":"57","author":"J Melchjorsen","year":"2011","journal-title":"J Acquir Immune Defic Syndr."},{"key":"ref80","doi-asserted-by":"publisher","first-page":"115-122","DOI":"10.1111\/j.1365-2893.2009.01168.x","article-title":"Hepatitis B viral load and risk for the liver cirrhosis and hepatocellular carcinoma in the Gambia, West Aftica.","volume":"17","author":"M Mendy","year":"2010","journal-title":"J Viral Hepat."},{"key":"ref47","first-page":"374-378","article-title":"Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients.","volume":"28","author":"N Papachrysos","year":"2015","journal-title":"Ann Gastroenterol."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/atm.2017.01.28","article-title":"Fibrosis assessment in patients with chronic hepatitis B virus (HBV) Infection.","volume":"5","author":"P Parikh","year":"2017","journal-title":"Ann Transl Med."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1181-1186","DOI":"10.4161\/hv.28332","article-title":"Obesity-Induced chronic inflammation is associated with the reduced efficacy of influenza vaccine.","volume":"10","author":"H Park","year":"2014","journal-title":"Hum Vaccin Immunother."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"195-204","DOI":"10.1007\/s10875-010-9483-5","article-title":"Hepatitis B e-antigen persistency is associated with the properties of HBV-specific Cd8 T cells in CHB patients.","volume":"31","author":"G Peng","year":"2011","journal-title":"J Clin Immunol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3389\/fimmu.2014.00619","article-title":"Diverse mechanism regulate the surface expression of immunotherapeutic target CTLA-4.","volume":"5","author":"H Schneider","year":"2014","journal-title":"Front Immunol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1494-1503","DOI":"10.1002\/hep.24249","article-title":"Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on poptosis-prone Cd8 T cells in persistent hepatitis B virus infection.","volume":"53","author":"A Schurich","year":"2011","journal-title":"Hepatology."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"671-678","DOI":"10.1002\/gepi.20617","article-title":"A test of hardy-weinberg equilibrium in structured populations.","volume":"35","author":"Q Sha","year":"2011","journal-title":"Genet Epidemiol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"9-17","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-a2b: relation to response and HBV genotype.","volume":"17","author":"M Sonneveld","year":"2012","journal-title":"Antivir Ther."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5427-5434","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance.","volume":"20","author":"M Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"10986-10997","DOI":"10.1128\/JVI.01124-08","article-title":"Host ethnicity and virus genotype shape the Hepatitis B virus-specific T-cell repertoire.","volume":"82","author":"A Tan","year":"2008","journal-title":"J Virol."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"E37927","DOI":"10.5812\/hepatmon.37927","article-title":"Manipulation of regulatory cells' responses to treatments for chronic hepatitis B virus infection.","volume":"16","author":"S Tavakolpour","year":"2016","journal-title":"Hepat Mon."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"205-209","DOI":"10.1016\/j.jhep.2012.11.007","article-title":"Dissecting the divergent effects of interferon-alpha on immune cells: Time to rethink combination therapy in chronic hepatitis B?","volume":"58","author":"R Thimme","year":"2013","journal-title":"J Hepatol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"818-829.e2","DOI":"10.1053\/j.gastro.2010.12.027","article-title":"Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.","volume":"140","author":"E Villa","year":"2011","journal-title":"Gastroenterology."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"S1117-S1120","DOI":"10.4103\/0973-1482.203604","article-title":"Association of cytotoxic T-lymphocyte antigen-4 + 49A\/G gene polymorphism with hepatocellular carcinoma risk in chinese.","volume":"14","author":"C Wang","year":"2018","journal-title":"J Cancer Res. Ther."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1471-2407-7-173","article-title":"Association of CTLA-4 gene polymorphisms with sporadic breast cancer in chinese Han population.","volume":"7","author":"L Wang","year":"2007","journal-title":"BMC Cancer."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2167-2177","DOI":"10.2165\/11319850-000000000-00000","article-title":"Predictors of treatment response in chronic hepatitis B.","volume":"69","author":"G Wong","year":"2009","journal-title":"Drugs."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"571-579","DOI":"10.1177\/135965350801300407","article-title":"Long-Term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.","volume":"13","author":"V Wong","year":"2008","journal-title":"Antivir Ther."},{"key":"ref70","first-page":"54-59","article-title":"CTLA-4 and its ligands on the surface of T- and B-lymphocyte subsets in chronic hepatitis B virus infection.","volume":"96","author":"C Wongjitrat","year":"2013","journal-title":"J Med Assoc Thail."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12985-016-0640-1","article-title":"HBsAg and HBeAg in the prediction of a clinical response to peginterferon a-2b therapy in chinese HBeAg-positive patients.","volume":"13","author":"S Yang","year":"2016","journal-title":"Virol J."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"E1694","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance.","volume":"6","author":"B Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"E15332","DOI":"10.5812\/hepatmon.15332","article-title":"Dynamic changes of treg and th17 cells and related cytokines closely correlate with the virological and biochemical response in chronic hepatitis B patients undergoing nucleos(t) ide analogues treatment.","volume":"13","author":"X Yu","year":"2013","journal-title":"Hepat Mon."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"11-20","DOI":"10.1016\/j.jhep.2008.12.019","article-title":"Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.","volume":"51","author":"S Zeuzem","year":"2009","journal-title":"J. Hepatol."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1-9","DOI":"10.1155\/2012\/789859","article-title":"Effects of telbivudine treatment on the circulating Cd4+ T-cell subpopulations in chronic hepatitis B patients.","volume":"2012","author":"Y Zheng","year":"2012","journal-title":"Mediat Inflamm."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:45:45Z","timestamp":1694691945000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":54,"URL":"https:\/\/doi.org\/10.12688\/f1000research.128116.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.154811.r199607","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.154811.r199608","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.154811.r199608","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.154811.r199607","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.154811.r199607, I Ketut Mariadi, Gastroenterohepatology Division, Department of Internal Medicine, Prof. Ngoerah General Hospitalglah General Hospital, Udayana University, Denpasar, 14 Sep 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2#referee-response-199607","order":0,"name":"referee-response-199607","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.154811.r199608, Hendra Koncoro, Department of Internal Medicine, Sint Carolus Hospital, Jakarta, 14 Sep 2023, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/11-1521\/v2#referee-response-199608","order":1,"name":"referee-response-199608","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}